160 related articles for article (PubMed ID: 36002754)
1. Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer.
Wu P; Zhang Z; Yang Z; Zhang C; Luo Y; Zhang G; Wang L; Xue Q; Sun N; He J
Cancer Immunol Immunother; 2023 Mar; 72(3):617-631. PubMed ID: 36002754
[TBL] [Abstract][Full Text] [Related]
2. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analyses of N
Luo Y; Zhang Z; Zheng B; Wu P; Zhang G; Wang L; Zeng Q; Yang Z; Xue L; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
Cancer Sci; 2022 Dec; 113(12):4289-4299. PubMed ID: 36047973
[TBL] [Abstract][Full Text] [Related]
4. m
Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
[TBL] [Abstract][Full Text] [Related]
5. Identification of a costimulatory molecule-based signature for predicting prognosis risk and immunotherapy response in patients with lung adenocarcinoma.
Zhang C; Zhang Z; Sun N; Zhang Z; Zhang G; Wang F; Luo Y; Che Y; He J
Oncoimmunology; 2020 Sep; 9(1):1824641. PubMed ID: 33457102
[TBL] [Abstract][Full Text] [Related]
6. m
Zhang Z; Zhang C; Yang Z; Zhang G; Wu P; Luo Y; Zeng Q; Wang L; Xue Q; Zhang Y; Sun N; He J
J Hematol Oncol; 2021 Nov; 14(1):190. PubMed ID: 34758859
[TBL] [Abstract][Full Text] [Related]
7. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
Front Immunol; 2021; 12():745769. PubMed ID: 34867972
[TBL] [Abstract][Full Text] [Related]
8. Prognostic costimulatory molecule-related signature risk model correlates with immunotherapy response in colon cancer.
Huang W; Su D; Liao X; Yang T; Lu Y; Zhang Z
Sci Rep; 2023 Jan; 13(1):789. PubMed ID: 36646765
[TBL] [Abstract][Full Text] [Related]
9. An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer.
Zhang Z; Luo Y; Zhang C; Wu P; Zhang G; Zeng Q; Wang L; Xue L; Yang Z; Zeng H; Zheng B; Tan F; Xue Q; Gao S; Sun N; He J
Cancer Cell Int; 2021 Dec; 21(1):691. PubMed ID: 34930244
[TBL] [Abstract][Full Text] [Related]
10. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
11. Landscape of costimulatory molecule signature in breast cancer and its prognostic significance.
Kang C; Yun F; Shi L; Jia Y; Liu X
Ann Transl Med; 2023 Jan; 11(2):59. PubMed ID: 36819560
[TBL] [Abstract][Full Text] [Related]
12. Construction of Prognostic Risk Model for Small Cell Lung Cancer Based on Immune-Related Genes.
Deng F; Tao F; Xu Z; Zhou J; Gong X; Zhang R
Comput Math Methods Med; 2022; 2022():7116080. PubMed ID: 36245844
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma.
Lin G; Yang Y; Feng Q; Zhan F; Sun C; Niu Y; Li G
Immunogenetics; 2022 Jun; 74(3):285-301. PubMed ID: 35119508
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection.
Guo Y; Yang L; Liu L; Wei J; Teng F; Zhang J; Zhu Y; Xing P; Li J
Thorac Cancer; 2020 Oct; 11(10):2782-2792. PubMed ID: 32779385
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Costimulatory Molecule Gene Signature to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.
Aye L; Song X; Yang J; Hu L; Sun X; Zhou J; Liu Q; Yu H; Wang D
Front Cell Dev Biol; 2021; 9():695533. PubMed ID: 34434928
[TBL] [Abstract][Full Text] [Related]
16. Identification of a prognostic immune-related signature for small cell lung cancer.
Xie Q; Chu H; Yi J; Yu H; Gu T; Guan Y; Liu X; Liang J; Li Y; Wang J
Cancer Med; 2021 Dec; 10(24):9115-9128. PubMed ID: 34741430
[TBL] [Abstract][Full Text] [Related]
17. Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma.
Zhou Y; Zhou X; Liu Q; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Yan Z
Dis Markers; 2022; 2022():8973721. PubMed ID: 36148160
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of Correlation between TTF-1 and Sensitivity to First-line Chemotherapy and Prognosis in Patients with Small Cell Lung Cancer].
Wang B; Feng N; Shi X; Qi Q; Chi X; Song T; Li H
Zhongguo Fei Ai Za Zhi; 2020 Jul; 23(7):547-553. PubMed ID: 32702788
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
